85608-70-4

Upstream product

• 623-69-8 1,3-dimethyl glycerol ether 
• 98-59-9 p-toluenesulfonyl chloride 
• 584-02-1 2-pentanol 

Downstream Products

• 1307864-29-4 C₃₄H₃₉NO₁₀ 
• 1307864-34-1 NSP-2,7-DMG-DMAE-Z-NHS 
• 1307864-33-0 C₅₁H₇₂N₄O₁₈S₂ 
• 1307864-32-9 C₄₆H₆₆N₄O₁₅S₂ 
• 1307864-31-8 C₃₆H₄₃NO₁₃S 
• 1307864-30-7 C₃₇H₄₅NO₁₃S 

Relevant academic research and scientific papers

PHENYL-HETEROARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I, and pharmaceutical compositions comprising such compounds

3-(AMINOARYL)-PYRIDINE COMPOUNDS

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are pharmaceutical compositions containing these compounds and methods of treating a disease or condition mediated by CDK9 using these compounds and compositions.

PYRIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

PYRIMIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a pyrimidine compound of formula (I): wherein one of X and Y but not both is N, and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tantomers, diastereomers, deuterated versions, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds

ZWITTERION-CONTAINING ACRIDINIUM COMPOUNDS

Hydrophilic, chemiluminescent acridinium compounds containing zwitterions are disclosed. These acridinium compounds, when used as chemiluminescent labels in immunochemistry assays and the like, exhibit decreased non-specific binding to solid phases and provide increased assay sensitivity.

Heteroaryl Compounds and Their Uses

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided is a method of treating a disease or condition mediated by CDK9.